NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 27, 2014– A scientific poster and lunch symposium at the upcoming Miami Breast Cancer Conference will focus new attention on genomic testing and molecular subtyping to refine breast Read More
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Low Recurrence Risk up to 25 Years after Diagnosis, Further Validating NEJM Study IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 17,2014 – A newly published Read More
Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference
Next-Generation Genomic Tests Determine Molecular Subtypes and Risk of Recurrence, Providing More Precise Prognosis and Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS, January 30, 2014 – Molecular subtyping provides a more precise prognosis and valuable Read More
Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDs’ Attention on Second-Generation Symphony Suite for Recurrence Risk and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 23, 2013 – Agendia’s innovations in genomic testing Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating the SymphonyTM suite Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 – Agendia, a leader in molecular cancer diagnostics, today announced that multiple established Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
‘High Risk’ Patients with Unusual Hormone Receptors May Be Undertreated IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 27, 2013 – Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset Read More
